Return to search

Tailwind Capital’s Cumberland closes buy of Mindlance Life Sciences

Cumberland Consulting Group, a portfolio company of Tailwind Capital, has completed its acquisition of Mindlance Life Sciences. No financial terms were disclosed. Clearsight Advisors served as the strategic and financial advisor to Mindlance in the transaction. Mindlance Life Sciences is a provider of advisory and tech services to pharmaceutical companies specializing in contract and revenue management, compliance and data analytics.

PRESS RELEASE

Clearsight Advisors, Inc. (“Clearsight”) is pleased to announce the completion of another highly successful transaction in their Professional Services Practice. Clearsight served as the exclusive strategic and financial advisor to Mindlance Inc., on the sale of its Life Sciences Consulting business, Mindlance Life Sciences, to Cumberland Consulting Group, LLC, a portfolio company of Tailwind Capital.
The Mindlance Life Sciences Consulting division provides advisory and technology implementation services to pharmaceutical companies specializing in contract and revenue management, compliance, and data analytics solutions. The company serves eight of the top 15 global pharmaceutical manufacturers. The Mindlance Life Sciences Consulting team will operate as a separate practice within Cumberland under the Cumberland brand and will continue to be led by its former Managing Partner Jeff Lee.
“Clearsight was the clear choice for us as we evaluated investment banks to guide us through this mission critical transaction. Clearsight’s unmatched industry knowledge and strategic relationships across both the consulting and life sciences spectrum allowed us to find the perfect partner in Cumberland. We couldn’t have chosen a better team to advise us on this transaction”, said Jeff Lee, Managing Partner, Mindlance Life Sciences.
With over 550 market participants in the United States alone, the life sciences industry represents one of the largest and most dynamic end-markets for software and consulting services globally. The life sciences industry continues to undergo a period of unprecedented competitive pressure and regulatory change, driving spending across mission-critical functional areas where measurable efficiencies and returns can be achieved. With a significant proportion of all sales and prices in the United States regulated by commercial or government contracts, contract/revenue management has emerged as a critical focus area for life sciences organizations to maximize revenues and reduce compliance risk.